These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34182611)

  • 1. Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
    Sadiq MW; Asimus S; Belvisi MG; Brailsford W; Fransson R; Fuhr R; Hagberg A; Hashemi M; Jellesmark Jensen T; Jonsson J; Keen C; Körnicke T; Kristensson C; Mäenpää J; Necander S; Nemes S; Betts J
    Br J Clin Pharmacol; 2022 Jan; 88(1):260-270. PubMed ID: 34182611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kγδ inhibition suppresses key disease features in a rat model of asthma.
    Pinkerton JW; Preite S; Piras A; Zervas D; Markou T; Freeman MS; Hofving T; Ivarsson E; Bonvini SJ; Brailsford W; Yrlid L; Belvisi MG; Birrell MA
    Respir Res; 2024 Apr; 25(1):175. PubMed ID: 38654248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
    Mariotti F; Govoni M; Lucci G; Santoro D; Nandeuil MA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3399-3410. PubMed ID: 30425469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.
    Pfeifer ND; Lo A; Bourdet DL; Colley K; Singh D
    Clin Transl Sci; 2021 Nov; 14(6):2556-2565. PubMed ID: 34318597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.
    Maden CH; Fairman D; Chalker M; Costa MJ; Fahy WA; Garman N; Lukey PT; Mant T; Parry S; Simpson JK; Slack RJ; Kendrick S; Marshall RP
    Eur J Clin Pharmacol; 2018 Jun; 74(6):701-709. PubMed ID: 29532104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
    Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
    J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers.
    Moreno O; Butler T; Zann V; Willson A; Leung P; Connor A
    Clin Ther; 2018 Nov; 40(11):1855-1867. PubMed ID: 30458930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.
    Wilson R; Jarvis E; Montembault M; Hamblin JN; Hessel EM; Cahn A
    Clin Ther; 2018 Aug; 40(8):1410-1417. PubMed ID: 30055824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
    Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
    Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers.
    Prothon S; Aurivillius M; Tehler U; Eriksson UG; Aggarwal A; Chen Y
    Drug Des Devel Ther; 2022; 16():485-497. PubMed ID: 35264846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
    Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers.
    Rein-Hedin E; Sjöberg F; Waters S; Sonesson C; Waters N; Huss F; Tedroff J
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1485-1494. PubMed ID: 34118179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Baratta M; Brake R; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1028-1043. PubMed ID: 34118178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.